Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat
Authors:
- Pu QinPQPu Qin
- Saul NeedleSNSaul Needle
- Connie L Erickson-MillerCEConnie L Erickson-Miller
- Kevin J DuffyKDKevin J Duffy
- Jennifer L AriaziJAJennifer L Ariazi
- Shufang ZhaoSZShufang Zhao
- Alan R OlzinskiAOAlan R Olzinski
- David J BehmDBDavid J Behm
- G C Teg PipesGPG C Teg Pipes
- Beat M JuckerBJBeat M Jucker
- Erding HuEHErding Hu
- 1 August 2010
- journal article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 56 (2) , 147-155
Abstract
Hypoxia inducible factors (HIFs) are transcription factors that are regulated by HIF-prolyl 4-hydroxylases (PHDs) in response to changes in oxygen tension. Once activated, HIFs play an important role in angiogenesis, erythropoiesis, proliferation, cell survival, inflammation, and energy metabolism. We hypothesized that GSK360A, a novel orally active HIF-PHD inhibitor, could facilitate local and systemic HIF-1 alpha signaling and protect the failing heart after myocardial infarction (MI). GSK360A is a potent (nanomolar) inhibitor of HIF-PHDs (PHD1>PHD2 = PHD3) capable of activating the HIF-1 alpha pathway in a variety of cell types including neonatal rat ventricular myocytes and H9C2 cells. Male rats treated orally with GSK360A (30 mg x kg x d) had a sustained elevation in circulating levels of erythropoietin and hemoglobin and increased hemoxygenase-1 expression in the heart and skeletal muscle. In a rat model of established heart failure with systolic dysfunction induced by ligation of left anterior descending coronary artery, chronic treatment with GSK360A for 28 days prevented the progressive reduction in ejection fraction, ventricular dilation, and increased lung weight, which were observed in the vehicle-treated animals, for up to 3 months. In addition, the microvascular density in the periinfarct region was increased (>2-fold) in GSK360A-treated animals. Treatment was well tolerated (survival was 89% in the GSK360A group vs. 82% in the placebo group). Chronic post-myocardial infarction treatment with a selective HIF PHD inhibitor (GSK360A) exerts systemic and local effects by stabilizing HIF-1 alpha signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These results suggest that HIF-PHD inhibitors may be suitable for the treatment of post-MI remodeling and heart failure.Keywords
This publication has 29 references indexed in Scilit:
- Anemia and Chronic Heart FailureJACC, 2008
- In Vivo Activation of Peroxisome Proliferator-Activated Receptor-δ Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty RatsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failureBlood, 2008
- Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol‐3 kinase and ERK1/2 activationBritish Journal of Pharmacology, 2008
- Anaemia in heart failure: a common interaction with renal insufficiency called the cardio-renal anaemia syndromeInternational Journal Of Clinical Practice, 2007
- A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against IschemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Prolyl hydroxylase inhibitor treatment confers whole‐animal hypoxia toleranceActa Physiologica, 2007
- HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligationJournal of Molecular and Cellular Cardiology, 2006
- Hypoxia Inducible Factor-1 Activation by Prolyl 4-Hydroxylase-2 Gene Silencing Attenuates Myocardial Ischemia Reperfusion InjuryCirculation Research, 2006
- Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia-Reperfusion InjuryCirculation, 2003